Dibenzoyl Thiamine

CAS No. 299-88-7

Dibenzoyl Thiamine( Bentiamine )

Catalog No. M21353 CAS No. 299-88-7

Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 Get Quote
50MG 27 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Dibenzoyl Thiamine
  • Note
    Research use only, not for human use.
  • Brief Description
    Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
  • Description
    Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Bentiamine
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    299-88-7
  • Formula Weight
    490.6
  • Molecular Formula
    C26H26N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:98 mg/mL (199.76 mM)
  • SMILES
    CC1=NC=C(C(=N1)N)CN(C=O)/C(=C(/CCOC(=O)C2=CC=CC=C2)\SC(=O)C3=CC=CC=C3)/C
  • Chemical Name
    Benzenecarbothioic acid S-(2-(((4-amino-2-methyl-5-pyrimidinyl)methyl)formylamino)-1-(2-(benzoyloxy)ethyl)-1-propenyl) ester

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Heywood R Wood JD Majeed SK.Tumorigenic and toxic effect of OS-dibenzoyl thiamine hydrochloride in prolonged dietary administration to rats.Toxicol Lett. 1985 Jul;26(1):53-8
molnova catalog
related products
  • TIBI

    TIBI is an ATP-competitive Rio1 inhibitor that acts in a similar manner to fungamycin and enhances the thermal stability of the enzyme.

  • C004019

    C004019 is a small molecule PROTAC capable of targeting tau for selective protein degradation from the cell, while recruiting tau and E3 ligase (Vhl) for selective enhancement of tau ubiquitination and proteollyzation. C004019 is a candidate for AD and related tau protein diseases.

  • Atractylenolide III

    Atractylenolide III may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury.